- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07942298
Utility of Respiratory Biomarker Guidance in Exacerbations (URGE)
Utility of Respiratory Biomarker Guidance in Exacerbations (URGE): a Pragmatic, Randomized, Open-Label, Single-Center Superiority Trial of Dual Point-of-Care Testing to Reduce Antibiotic Use in Adults Presenting to the Emergency Department With Asthma or COPD Exacerbations
People with asthma or chronic obstructive pulmonary disease (COPD) often come to the emergency department because their breathing suddenly gets worse. These flare-ups are called exacerbations. Many of these episodes are caused by viruses or inflammation, not bacteria. However, clinicians still frequently prescribe antibiotics, even when they are unlikely to help. Unnecessary antibiotic use can cause side effects, increase healthcare costs, and contribute to antibiotic resistance, which is a growing public health problem.
The URGE study aims to find a better way to decide when antibiotics are truly needed during asthma or COPD attacks in the emergency department. The study will test whether using two rapid bedside tests can safely reduce unnecessary antibiotic prescriptions.
The first test is a rapid molecular test that looks for common respiratory viruses and certain bacteria using a nasopharyngeal swab. Results are available within about 15 to 20 minutes. The second test measures C-reactive protein (CRP) from a small blood sample. CRP is an inflammation marker that tends to be higher when a bacterial infection is present. Together, these tests give doctors quick information about whether an infection is likely viral, bacterial, or non-infectious.
URGE will recruit 200 adults who come to the emergency department with an asthma or COPD exacerbation to take part in the study. After providing consent, participants will be randomly assigned to one of two groups. In both groups, participants will complete both rapid tests. In one group, the test results will be shared with the treating doctor right away and can be used to help guide treatment decisions. In the other group, the doctor will not see the test results, and care will follow usual practice. Doctors will always be free to make their own clinical decisions, regardless of test results.
The main outcome the study will measure is whether or not patients are prescribed antibiotics when they leave the emergency department or are admitted to hospital. The study will also examine how long patients take antibiotics, hospital admissions, return visits to healthcare services, and patient satisfaction. Participants will be followed up by phone and through medical record review at 7 days and 30 days after their emergency visit to ensure they recover safely.
The URGE trial will study tests that are already approved and commonly used in healthcare. The goal is not to deny needed treatment, but to better match treatment to the cause of the flare-up. If successful, this approach could reduce unnecessary antibiotic use, improve patient care, and support safer, more sustainable treatment of asthma and COPD exacerbations in emergency departments.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Acute exacerbations of asthma and COPD are frequent causes of emergency department (ED) visits worldwide, with a substantial proportion of patients receiving antibiotics - often inappropriately - despite a likely viral or non-infectious etiology [1,2]. This practice contributes to antimicrobial resistance, patient harm, and unnecessary healthcare costs [3-8]. While guidelines emphasize the judicious use of antibiotics, real-time decision-making in the ED is often constrained by diagnostic uncertainty. Current approaches recommended by guidelines (GINA, GOLD, INESSS) rely heavily on symptom severity and do not systematically integrate host inflammatory or pathogen-specific data [9-12].
Leveraging evidence from previous randomized controlled trial post hoc analyses, the URGE trial is a pragmatic, randomized, open-label study designed to evaluate whether dual point-of-care testing (POCT) - combining rapid molecular microbial PCR (Polymerase Chain Reaction) testing and C-reactive protein (CRP) - can reduce antibiotic use in adults presenting to the ED with an asthma or COPD attack. This dual biomarker strategy aims to enhance diagnostic precision by integrating pathogen detection with host inflammatory responses, thereby guiding real-time, targeted decisions.
A total of 200 patients will be targeted, recruiting until at least 124 analysable patients have completed the trial. All participants will undergo microbial PCR and CRP testing after randomisation and will be managed in accordance with current clinical practice guidelines. In the intervention group, PCR and CRP results will be available to treating clinicians at the time of evaluation and used to inform management decisions. In the control group, test results will not be available to clinicians. The primary outcome is the proportion of patients prescribed antibiotics at ED discharge. Secondary outcomes include antibiotic duration, hospital admissions, revisit rates, and patient acceptability.
URGE is grounded in a growing body of evidence suggesting that either molecular microbial PCR alone or CRP can reduce antibiotic prescribing in acute respiratory illness. Molecular microbial POCT enables rapid identification of respiratory pathogens, whereas CRP reflects the host's systemic inflammatory response - particularly in response to bacterial infections- thereby facilitating early exclusion of a bacterial etiology. However, to date, no randomized trials have assessed the combined impact of these two complementary biomarkers in a real-world emergency care setting. URGE is the first study to evaluate whether integrating both markers into a unified triage strategy can synergistically improve antibiotic stewardship in patients with asthma and COPD attacks.
If successful, the URGE trial will pave the way for a biomarker-guided, proactive approach to antibiotic stewardship in acute airway disease, shifting ED management from a "treat all" paradigm to one that integrates real-time microbial identification by PCR and CRP-based inflammatory profiling. This study will inform the design of larger multicenter implementation trials and help transform care for respiratory infections in the ED.
This protocol is reported in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2025 reporting guideline [13].
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 5N4
- CIUSSS de l'Estrie-CHUS, Hôpital Fleurimont
-
Investigatore principale:
- Simon Couillard, MD
-
Contatto:
- Email: s.couillard@usherbrooke.ca
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Adults aged ≥18 years at the time of signing the informed consent.
-
Presenting to the ED with a clinical diagnosis of asthma or COPD exacerbation, defined as an acute (<14 days) worsening of respiratory symptoms beyond baseline (e.g. increased dyspnea, cough, sputum, or wheezing) requiring urgent evaluation.
-
Established diagnosis of asthma or COPD for > 1 month*, based on:
-
For asthma: documented variability in airflow limitation (e.g., spirometric reversibility ≥12% and ≥200 mL in FEV1, or positive bronchial provocation testing), consistent with GINA 2025.
-
For COPD: post-bronchodilator FEV1/FVC <0.70 or below the LLN with ≥10 pack-years smoking history and compatible symptoms, consistent with GOLD 2026.
*Patients with physician-diagnosed disease, without objective testing, may undergo confirmatory testing < 3 months after URGE trial participation to confirm eligibility.
-
Antibiotics were not ordered at the time of randomisation.
-
Able to provide signed, informed consent within the ED care window.
-
Willingness to undergo molecular microbial PCR and CRP at the point-of-care before antibiotic decision.
Exclusion Criteria:
Medical conditions
- Clinical concern for sepsis at the time of enrolment: Altered mental status or Systolic blood pressure ≤ 100 mm Hg, unless consistent with the patient's usual baseline and without other signs of hypoperfusion.
- Current systemic antibiotic for acute respiratory illness at time of evaluation.
- Chronic systemic corticosteroid use for any indication. The first systemic corticosteroid dose given before or in the ED for the index exacerbation is permitted and does not constitute exclusion.
- Known significant chronic respiratory disease other than asthma or COPD, including interstitial lung disease, pulmonary hypertension, cystic fibrosis, clinically significant bronchiectasis.
- Acute use of non-invasive ventilation (NIV).
- History of active malignancy within the past 6 months, excluding: non-melanoma skin cancer or localized cervical dysplasia / in situ cancer.
- Significant immunosuppression or ongoing systemic immunosuppressive therapy (e.g., methotrexate or other immunosuppressive disease-modifying antirheumatic drugs (DMARDs), transplant recipients, chemotherapy).
- End-stage organ disease (e.g., decompensated heart failure, end-stage renal or liver disease).
- Severe cognitive impairment or inability to provide informed consent.
- Pregnancy or breastfeeding.
- Previous participation in the URGE study (participants may be enrolled only once).
- Known (test-positive) viral infection within the past 7 days.
- Diagnosis of pneumonia with chest X-ray made at the index visit at the clinician's discretion.
- Concurrent acute coronary syndrome (either primary or secondary).
- Decompensated heart failure.
- New-onset arrhythmia.
- Vaccination against influenza with FluMist® within 14 days prior.
Logistical or Operational Exclusions
- Patient is unable or unwilling to undergo both POCTs.
- Expected discharge to long-term care facility or hospice.
- Patient self-discharges before meeting emergency care physician
Other exclusions
-Individuals are accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalised.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: POCT results disclosed
Dual POCT results (multiplex PCR + CRP) are disclosed in real time to the treating physician, together with a predefined advisory PCR+CRP antibiotic algorithm; results are communicated to the patient. Clinicians may override the algorithm. |
Rapid, point-of-care (POC) tests at the ED visit
Altri nomi:
Rapid, point-of-care (POC) tests at the ED visit.
Altri nomi:
Multiplex PCR and CRP results are disclosed in real time to the treating physician (written note in the EMR triage section), together with a predefined advisory antibiotic algorithm. Results are communicated to the patient by the treating physician. Clinicians may override the algorithm at any time. |
|
Altro: POCT results non disclosed
Participants undergo the same dual POCT (PCR + CRP) under identical conditions, but results are not disclosed to the treating physician or the participant during the index visit. Usual care per clinician judgment. |
Rapid, point-of-care (POC) tests at the ED visit
Altri nomi:
Rapid, point-of-care (POC) tests at the ED visit.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of participants prescribed antibiotics at ED discharge
Lasso di tempo: At ED discharge or hospital admission (assessed up to 5 days)
|
Prescription of any antibiotic at ED discharge |
At ED discharge or hospital admission (assessed up to 5 days)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of patients receiving only a single dose of antibiotics
Lasso di tempo: During ED stay (assessed up to 5 days)
|
Single-dose antibiotic administration |
During ED stay (assessed up to 5 days)
|
|
Proportion of patients receiving intravenous (IV) antibiotics
Lasso di tempo: During ED stay (assessed up to 5 days)
|
Intravenous antibiotic administration during ED stay |
During ED stay (assessed up to 5 days)
|
|
Total duration of oral antibiotic use
Lasso di tempo: From initiation to discontinuation (assessed up to 30 days)
|
Number of days of oral antibiotic therapy |
From initiation to discontinuation (assessed up to 30 days)
|
|
Total duration of IV antibiotic use
Lasso di tempo: During ED stay and/or hospitalization (assessed up to 30 days)
|
Number of days of intravenous antibiotic therapy |
During ED stay and/or hospitalization (assessed up to 30 days)
|
|
Antibiotic prescription after ED discharge
Lasso di tempo: Day 7 and Day 30
|
New antibiotic prescriptions after discharge for patients who did not receive one at discharge, and the time until that prescription was issued. |
Day 7 and Day 30
|
|
ED length of stay
Lasso di tempo: From ED registration to ED discharge or admission order (assessed up to 5 days)
|
Hours from ED registration to discharge or admission order |
From ED registration to ED discharge or admission order (assessed up to 5 days)
|
|
Hospital admission rate
Lasso di tempo: During index ED visit (assessed up to 5 days)
|
Admission to hospital after ED evaluation |
During index ED visit (assessed up to 5 days)
|
|
Length of hospital stay
Lasso di tempo: From hospital admission to discharge (assessed up to 30 days)
|
Duration from hospital admission to discharge |
From hospital admission to discharge (assessed up to 30 days)
|
|
Corticosteroid prescribing at ED discharge
Lasso di tempo: At ED discharge (assessed up to 5 days)
|
Prescription of systemic corticosteroids |
At ED discharge (assessed up to 5 days)
|
|
Oseltamivir prescribing at ED discharge
Lasso di tempo: At ED discharge (assessed up to 5 days)
|
Oseltamivir prescription in PCR-confirmed influenza |
At ED discharge (assessed up to 5 days)
|
|
Time to oseltamivir initiation
Lasso di tempo: From randomization to first oseltamivir dose (assessed up to 30 days)
|
Time from randomization to first oseltamivir dose in PCR-confirmed influenza |
From randomization to first oseltamivir dose (assessed up to 30 days)
|
|
Duration of oseltamivir use
Lasso di tempo: Through Day 30 follow-up
|
Number of days of oseltamivir treatment in PCR-confirmed influenza |
Through Day 30 follow-up
|
|
Isolation precautions applied (mask) during ED stay
Lasso di tempo: During ED stay, from ED arrival to ED discharge (assessed up to 5 days)
|
Participants with documented initiation of respiratory isolation precautions (mask use) at any time during the ED stay. |
During ED stay, from ED arrival to ED discharge (assessed up to 5 days)
|
|
Adverse events (AEs)
Lasso di tempo: Index ED visit, Day 7, and Day 30 follow-up
|
Proportion of participants with ≥1 adverse event (AE) and ≥1 serious adverse event (SAE). Severity according to CTCAE v5.0 (mild, moderate, severe). |
Index ED visit, Day 7, and Day 30 follow-up
|
|
In-hospital mortality
Lasso di tempo: Index ED visit and index hospital admission, up to discharge (assessed up to 30 days)
|
Death occurring during the index ED visit or during the subsequent index hospitalization (if admitted). Reported as all-cause and asthma/COPD-related. |
Index ED visit and index hospital admission, up to discharge (assessed up to 30 days)
|
|
Unscheduled primary care consultation
Lasso di tempo: Day 7 and Day 30 follow-up.
|
Any unplanned primary care visits after the index ED encounter. Reported as all-cause and asthma/COPD-related. |
Day 7 and Day 30 follow-up.
|
|
Unscheduled ED visits
Lasso di tempo: Day 7 and Day 30 follow-up
|
Return visits to any ED after the index encounter. Reported as all-cause and asthma/COPD-related |
Day 7 and Day 30 follow-up
|
|
Unscheduled hospital admission
Lasso di tempo: Day 7 and Day 30 follow-up
|
Any unplanned hospital admission after the index encounter. Reported as all-cause and asthma/COPD-related |
Day 7 and Day 30 follow-up
|
|
Mortality (all-cause and asthma/COPD-related)
Lasso di tempo: Day 7 and Day 30 follow-up
|
Death after the index ED visit, reported as all-cause and asthma/COPD-related |
Day 7 and Day 30 follow-up
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to obtain POCT PCR results
Lasso di tempo: Index ED visit (assessed up to 5 days)
|
Time from documented sample collection to PCR result availability on the POCT platform (device timestamp and/or documented availability for disclosure) |
Index ED visit (assessed up to 5 days)
|
|
Time to obtain POCT CRP results
Lasso di tempo: Index ED visit (assessed up to 5 days)
|
Time from documented sample collection to CRP result availability on the platform (device timestamp and/or documented availability for disclosure) |
Index ED visit (assessed up to 5 days)
|
|
Prevalence and distribution of respiratory viruses and bacteria detected
Lasso di tempo: Index ED visit (assessed up to 5 days)
|
Pathogen type detected by PCR |
Index ED visit (assessed up to 5 days)
|
|
Prevalence of influenza virus detected
Lasso di tempo: Index ED visit (assessed up to 5 days)
|
PCR-confirmed influenza detection |
Index ED visit (assessed up to 5 days)
|
|
Antibiotic decision-POCT concordance
Lasso di tempo: At ED discharge (assessed up to 5 days)
|
Algorithm-recommended antibiotic decision (discourage / consider / recommend) derived from the predefined CRP+PCR algorithm; and observed antibiotic prescribing status at ED discharge (yes/no), cross-classified with POCT profile (CRP strata and PCR result categories). |
At ED discharge (assessed up to 5 days)
|
|
Antibiotic prescribing based on CRP strata
Lasso di tempo: At ED discharge (assessed up to 5 days)
|
CRP level category (<20, 20-40, >40 mg/L) |
At ED discharge (assessed up to 5 days)
|
|
Time to antibiotic initiation
Lasso di tempo: From randomization to first antibiotic dose (assessed up to 30 days)
|
Time from randomization to first antibiotic administration (IV or oral) |
From randomization to first antibiotic dose (assessed up to 30 days)
|
|
Atypical pathogen-targeted antibiotic (e.g. macrolide) use among participants with positive PCR for atypical bacteria.
Lasso di tempo: During ED stay (assessed up to 5 days)
|
Initiation of an atypical pathogen-targeted antibiotic (e.g. macrolide) among participants with PCR-detected atypical bacteria |
During ED stay (assessed up to 5 days)
|
|
Patient satisfaction and acceptability of POCT strategy
Lasso di tempo: At ED visit (assessed up to 5 days)
|
Patient-reported satisfaction |
At ED visit (assessed up to 5 days)
|
|
POCT-Laboratory PCR concordance
Lasso di tempo: At ED visit (assessed up to 5 days)
|
Concordance between POCT PCR results and routine laboratory results when both are performed during the index ED visit |
At ED visit (assessed up to 5 days)
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Malattia cronica
- Attributi della malattia
- Malattie del sistema immunitario
- Malattie delle vie respiratorie
- Malattie polmonari
- Malattie bronchiali
- Malattie polmonari, ostruttive
- Ipersensibilità respiratoria
- Ipersensibilità, immediata
- Ipersensibilità
- Condizioni patologiche, segni e sintomi
- Malattia polmonare, cronica ostruttiva
- Asma
Altri numeri di identificazione dello studio
- 0002
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
De-identified individual participant data (IPD) will be shared for all participants who consent to third-party data sharing. This includes the data underlying the published results: baseline demographic and clinical characteristics, eligibility variables, randomization arm, point-of-care test results (multiplex PCR and CRP), intervention adherence (POCT disclosure and algorithm concordance), primary and secondary outcomes (antibiotic prescribing, healthcare utilization, mortality), and adverse events. A complete data dictionary will be provided with the dataset. Data will be coded with study IDs, and all direct identifiers will be removed to prevent re-identification.
Periodo di condivisione IPD
Beginning after publication of the primary outcome results and available for at least 15 years thereafter.
Criteri di accesso alla condivisione IPD
Researchers must submit a research proposal to the study investigators. Access requires approval by the investigators, a signed data-sharing agreement, and ethics approval where applicable. Data will be provided through a controlled-access repository at Université de Sherbrooke.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .